IsoPlexis Corporation has raised $13.5 million in a Series B financing round.

The round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwood Capital.

IsoPlexis, a privately held life sciences company, is developing novel technologies at the forefront of the revolution in immunity-based treatments of cancer.